SRR821602
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR599510 | GTEX | — | 0.992 |
| 2 | SRR607445 | GTEX | — | 0.953 |
| 3 | SRR1335446 | GTEX | — | 0.952 |
| 4 | SRR608598 | GTEX | — | 0.948 |
| 5 | SRR1467294 | GTEX | — | 0.942 |
| 6 | SRR818469 | GTEX | — | 0.937 |
| 7 | BS_HHPA8NJ2 | Med | Medulloblastoma | 0.935 |
| 8 | SRR602131 | GTEX | — | 0.932 |
| 9 | SRR1389059 | GTEX | — | 0.931 |
| 10 | MDT-AP-1108 | Med | Medulloblastoma | 0.931 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.584 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.556 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.542 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.522 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.504 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.487 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.463 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.427 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.420 | Inavolisib | — uncovered |
| COMPLEMENT | 0.414 | Inavolisib | — uncovered |
| COAGULATION | 0.396 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.324 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.296 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.231 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.214 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.184 | Inavolisib | — uncovered |
| HYPOXIA | 0.177 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.162 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.156 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.145 | Cobimetinib | — uncovered |